SYK really changed my financial situation, made roughly $220k the past few months, been getting my stock alerts from underground stock alerts (google em). Hope you guys have been doing as well with trading as I have.
Temple University now on board with their first Mako. Also, the Adventist system continues to add units with the latest being Sonora Medical Center (Adventist also continuing to add Mazor Renaissance units).
Sentiment: Strong Buy
4:49 pm Stryker announces definitive agreement to acquire PivotMedical in an all-cash transaction; transaction is expected to be neutral to Stryker's 2014 EPS, ex-items
Sentiment: Strong Buy
I sold some shares Friday. Seems like management is becoming more promotional (for instance, neglecting amortization in their eps estimates) as earnings growth slows (though due to absorbing the MAKO losses), and the valuation is no longer exciting.
I know I can look it up however didn't earning come out already and the stock has gone up 12 points since?
This is the most cynical and manipulative headline I've seen from Stryker in my 8 years owning the stock! It is the same dividend rate they paid last quarter! So every quarter where the dividend is higher than a year earlier, we're going to see a headline like this? I guess now management has decided to become pumpers.
"Kalamazoo, Michigan - February 12, 2014 - Stryker Corporation (SYK) announced that its Board of Directors has increased its dividend 15%, compared to the prior year, by declaring a quarterly dividend of $0.305 per share payable "
Read the earnings call transcript, liked what I read about their plans for MAKO.
Not a beat on guidance. Until this year, SYK included the costs of amortization of intangibles in their reported guidance and earnings. In 2014 they will. This would have added $0.26/sh of eps to 2013. When you put their guidance and analysts previous consensus on the same basis, analysts were expecting $4.58+$0.26 = $4.84/share. Right in the middle of the guidance range.
Stryker Reports Fourth Quarter and Full Year 2013 Results and 2014 Outlook
Kalamazoo, Michigan - January 22, 2014 - Stryker Corporation (NYSE:SYK) reported operating results for the fourth quarter and full year 2013:
Fourth Quarter Highlights
Net sales growth of 5.6% to $2.5 billion
•Reconstructive 5.8% or 8.0% constant currency
•MedSurg 5.4% or 6.6% constant currency
•Neurotechnology and Spine 5.4% or 7.5% constant currency
Reported diluted net earnings per share increased 42.3% to $1.01
Adjusted diluted net earnings per share(1) increased 7.9% to $1.23
Full Year Highlights
Net sales growth of 4.2% to $9.0 billion
•Reconstructive 4.8% or 6.9% constant currency
•MedSurg 2.9% or 3.8% constant currency
•Neurotechnology and Spine 5.6% or 7.7% constant currency
Reported diluted net earnings per share decreased 22.4% to $2.63
Adjusted diluted net earnings per share(1) increased 3.9% to $4.23
Cash flow from operations increased 13.8% to $1.9 billion
"We are pleased with our organic sales growth and operational earnings achieved in 2013. With our broad based product portfolio and commitment to innovation and globalization we are well positioned to build on this momentum in 2014," stated Kevin A. Lobo, President and Chief Executive Officer.
Consolidated net sales of $2.5 billion and $9.0 billion increased 5.6% and 4.2% in the quarter and full year, respectively. Net sales in the quarter grew by 7.3% due to increased unit volume and changes in product mix and 1.5% as a result of acquisitions. Net sales in the quarter were unfavorably impacted by 1.4% due to changes in price and 1.8% due to the unfavorable impact of foreign currency exchange rates on net sales. Excluding the impact of acquisitions, net sales in the quarter increased 5.8% in constant currency.
Reconstructive net sales of $1.1 billion increased 5.8% in the quarter, as reported, and 8.0% in constant currency. Net sales grew by 7.1% due to in
Stryker Corp. (NYSE: SYK) reported Q4 EPS of $1.23, $0.01 better than the analyst estimate of $1.22. Revenue for the quarter came in at $2.47 billion versus the consensus estimate of $2.44 billion.
Stryker Corp. sees FY2014 EPS of $4.75-$4.90, versus the consensus of $4.58. Organic sales growth in 2014 is expected to be in the range of 4.5% to 6.0%. If foreign currency exchange rates hold near current levels, we expect net sales in the first quarter and full year of 2014 to be negatively impacted by less than 1.0%.
Sentiment: Strong Buy